Global Lung Cancer Diagnostics Market

Lung Cancer Diagnostics Comprehensive Study by Type (CA Test, HER2 Tests, ALK Tests, Angiogenesis Inhibitor, KRAS Mutation Tests, Others), Application (Hospital Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes, Others), Indication (Non-Small-Cell Lung Cancer (Large Cell Carcinoma, Adenocarcinoma, Squamous Cell Carcinoma, Others), Small-Cell Lung Cancer (Small-Cell Lung Carcinoma, Combined Small-Cell Lung Carcinoma)), Imaging Techniques (MRI, CT-Scan, X-Ray) Players and Region - Global Market Outlook to 2030

Lung Cancer Diagnostics Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Lung Cancer Diagnostics
A lung cancer diagnosis can be defined as a set of tests and diagnostic procedures used in the treatment of lung cancer, including imaging, tumor screening, sputum cytology tests, and biopsy. According to the World Health Organization (WHO), at least 6 million people die from tobacco consumption every year. Tobacco, the leading cause of lung cancer, may lead the lung cancer diagnostic market to grow. Other factors such as alcohol consumption, infectious agents such as human papillomavirus (HPV), environmental pollution, and occupational carcinogens also contribute to increased lung cancer patients. The need for more efficient diagnostic systems is that only 15% of lung cancers are diagnosed, while the remaining undiagnosed cancers develop into more aggressive forms, bringing the 5-year survival rate in these detected patients to just 4% reduces late-stage lung cancer. An estimated 14 million adults have been diagnosed with the disease worldwide, with the prevalence expected to reach 21.7 million by 2030. Increased exposure to radon, asbestos, secondhand smoke, air pollution, or other factors causes lung cancer in nonsmokers. Genetics also plays an important role in the occurrence of disease in non-smokers. Occupational exposures to diesel fumes, asbestos, and other chemicals increase the risk of cancer. Increasing technological advances such as the development of specific biomarkers facilitate the tailored treatment approach for malignant lung diseases that ultimately drives the market for lung cancer diagnostics over the forecast period. The increasing awareness of the population and the availability of state funds and private funds for research and development of better tumor diagnosis tools are driving the growth of the industry further.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Lung Cancer Diagnostics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Roche Diagnostics (Switzerland), BioMérieux (France), Qiagen (Germany), Agilent Technologies (United States), AstraZeneca (United Kingdom), Sanofi (France), Janssen Pharmaceuticals (Belgium), GE Healthcare (United States), Hologic (United States), Koninklijke Philips N.V (Netherlands), Danaher (United States), Illumina, Inc. (United States), Abbott Laboratories (United States), Thermo Fisher Scientific, Inc. (United States), Quest Diagnostics (United States), Courtagen Life Sciences, Inc. (United States), DiagnoCure Inc. (Canada), BioMark Diagnostics Inc. (Canada), HalioDx SAS (France) and NeoGenomics (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are NanoString Technologies, Inc. (United States), Myriad Genetics, Inc. (United States), BioTheranostics, Inc. (United States) and EXACT Sciences Corporation (United States).

Segmentation Overview
AMA Research has segmented the market of Global Lung Cancer Diagnostics market by Type (CA Test, HER2 Tests, ALK Tests, Angiogenesis Inhibitor, KRAS Mutation Tests and Others), Application (Hospital Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes and Others) and Region.



On the basis of geography, the market of Lung Cancer Diagnostics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Indication, the sub-segment i.e. Non-Small-Cell Lung Cancer [Large Cell Carcinoma, Adenocarcinoma, Squamous Cell Carcinoma, Others] will boost the Lung Cancer Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Imaging Techniques, the sub-segment i.e. MRI will boost the Lung Cancer Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
A Rising Trend in Campaigning For Increasing Awareness of the Symptoms of Lung Cancer and The Rise in Accessibility of Private and Government Funds for R&D to Develop Better Tumor Diagnostic Tools

Market Growth Drivers:
A Rise in the Prevalence of Smoking, The Increasing Awareness Levels amongst the Population, The Presence of a Favorable Reimbursement Framework and The Rising Penetration of the Advanced Lung Cancer Diagnostic Tools

Challenges:
Lack of Skilled Personnel

Restraints:
A Dearth of Awareness in Under Developed Regions

Opportunities:
Introduction of Technological Advancements With Regard To Accuracy and The Increasing Health Care Expenditure

Market Leaders and their expansionary development strategies
In March 2024, Maverix Medical that it has closed its acquisition of Cirrus Bio, which it is incorporating into a new diagnostics arm, Maverix Dx, with plans to bring to market a suite of lung cancer diagnostics via additional investment and acquisitions. Financial terms of the deal were not disclosed.
In July 2020, Roche had announced the CE-IVD launch of its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for non-small cell lung cancer (NSCLC). The algorithm enabled pathologists to automatically evaluate scanned slide images that are objective, reproducible, and can aid diagnosis and ultimately targeted treatment options for patients. The algorithm was faster, and more accurate diagnoses are crucial in non-small cell lung cancer, which accounts for about 85 percent of all lung cancer cases.


Key Target Audience
Providers of Lung Cancer Diagnostics, Potential Technology Investors, Regulatory & Government Bodies, End Users, Downstream Vendors and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • CA Test
  • HER2 Tests
  • ALK Tests
  • Angiogenesis Inhibitor
  • KRAS Mutation Tests
  • Others
By Application
  • Hospital Associated Labs
  • Independent Diagnostic Laboratories
  • Cancer Research Institutes
  • Others
By Indication
  • Non-Small-Cell Lung Cancer [Large Cell Carcinoma, Adenocarcinoma, Squamous Cell Carcinoma, Others]
  • Small-Cell Lung Cancer [Small-Cell Lung Carcinoma, Combined Small-Cell Lung Carcinoma]

By Imaging Techniques
  • MRI
  • CT-Scan
  • X-Ray

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. A Rise in the Prevalence of Smoking
      • 3.2.2. The Increasing Awareness Levels amongst the Population
      • 3.2.3. The Presence of a Favorable Reimbursement Framework
      • 3.2.4. The Rising Penetration of the Advanced Lung Cancer Diagnostic Tools
    • 3.3. Market Challenges
      • 3.3.1. Lack of Skilled Personnel
    • 3.4. Market Trends
      • 3.4.1. A Rising Trend in Campaigning For Increasing Awareness of the Symptoms of Lung Cancer
      • 3.4.2. The Rise in Accessibility of Private and Government Funds for R&D to Develop Better Tumor Diagnostic Tools
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Lung Cancer Diagnostics, by Type, Application, Indication, Imaging Techniques and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Lung Cancer Diagnostics (Value)
      • 5.2.1. Global Lung Cancer Diagnostics by: Type (Value)
        • 5.2.1.1. CA Test
        • 5.2.1.2. HER2 Tests
        • 5.2.1.3. ALK Tests
        • 5.2.1.4. Angiogenesis Inhibitor
        • 5.2.1.5. KRAS Mutation Tests
        • 5.2.1.6. Others
      • 5.2.2. Global Lung Cancer Diagnostics by: Application (Value)
        • 5.2.2.1. Hospital Associated Labs
        • 5.2.2.2. Independent Diagnostic Laboratories
        • 5.2.2.3. Cancer Research Institutes
        • 5.2.2.4. Others
      • 5.2.3. Global Lung Cancer Diagnostics by: Indication (Value)
        • 5.2.3.1. Non-Small-Cell Lung Cancer [Large Cell Carcinoma, Adenocarcinoma, Squamous Cell Carcinoma, Others]
        • 5.2.3.2. Small-Cell Lung Cancer [Small-Cell Lung Carcinoma, Combined Small-Cell Lung Carcinoma]
      • 5.2.4. Global Lung Cancer Diagnostics by: Imaging Techniques (Value)
        • 5.2.4.1. MRI
        • 5.2.4.2. CT-Scan
        • 5.2.4.3. X-Ray
      • 5.2.5. Global Lung Cancer Diagnostics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Lung Cancer Diagnostics (Price)
      • 5.3.1. Global Lung Cancer Diagnostics by: Type (Price)
  • 6. Lung Cancer Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche Diagnostics (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. BioMérieux (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Qiagen (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Agilent Technologies (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Janssen Pharmaceuticals (Belgium)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GE Healthcare (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Hologic (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Koninklijke Philips N.V (Netherlands)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Danaher (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Illumina, Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Abbott Laboratories (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Quest Diagnostics (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Courtagen Life Sciences, Inc. (United States)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. DiagnoCure Inc. (Canada)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
      • 6.4.18. BioMark Diagnostics Inc. (Canada)
        • 6.4.18.1. Business Overview
        • 6.4.18.2. Products/Services Offerings
        • 6.4.18.3. Financial Analysis
        • 6.4.18.4. SWOT Analysis
      • 6.4.19. HalioDx SAS (France)
        • 6.4.19.1. Business Overview
        • 6.4.19.2. Products/Services Offerings
        • 6.4.19.3. Financial Analysis
        • 6.4.19.4. SWOT Analysis
      • 6.4.20. NeoGenomics (United States)
        • 6.4.20.1. Business Overview
        • 6.4.20.2. Products/Services Offerings
        • 6.4.20.3. Financial Analysis
        • 6.4.20.4. SWOT Analysis
  • 7. Global Lung Cancer Diagnostics Sale, by Type, Application, Indication, Imaging Techniques and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Lung Cancer Diagnostics (Value)
      • 7.2.1. Global Lung Cancer Diagnostics by: Type (Value)
        • 7.2.1.1. CA Test
        • 7.2.1.2. HER2 Tests
        • 7.2.1.3. ALK Tests
        • 7.2.1.4. Angiogenesis Inhibitor
        • 7.2.1.5. KRAS Mutation Tests
        • 7.2.1.6. Others
      • 7.2.2. Global Lung Cancer Diagnostics by: Application (Value)
        • 7.2.2.1. Hospital Associated Labs
        • 7.2.2.2. Independent Diagnostic Laboratories
        • 7.2.2.3. Cancer Research Institutes
        • 7.2.2.4. Others
      • 7.2.3. Global Lung Cancer Diagnostics by: Indication (Value)
        • 7.2.3.1. Non-Small-Cell Lung Cancer [Large Cell Carcinoma, Adenocarcinoma, Squamous Cell Carcinoma, Others]
        • 7.2.3.2. Small-Cell Lung Cancer [Small-Cell Lung Carcinoma, Combined Small-Cell Lung Carcinoma]
      • 7.2.4. Global Lung Cancer Diagnostics by: Imaging Techniques (Value)
        • 7.2.4.1. MRI
        • 7.2.4.2. CT-Scan
        • 7.2.4.3. X-Ray
      • 7.2.5. Global Lung Cancer Diagnostics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Lung Cancer Diagnostics (Price)
      • 7.3.1. Global Lung Cancer Diagnostics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Lung Cancer Diagnostics: by Type(USD Million)
  • Table 2. Lung Cancer Diagnostics CA Test , by Region USD Million (2018-2023)
  • Table 3. Lung Cancer Diagnostics HER2 Tests , by Region USD Million (2018-2023)
  • Table 4. Lung Cancer Diagnostics ALK Tests , by Region USD Million (2018-2023)
  • Table 5. Lung Cancer Diagnostics Angiogenesis Inhibitor , by Region USD Million (2018-2023)
  • Table 6. Lung Cancer Diagnostics KRAS Mutation Tests , by Region USD Million (2018-2023)
  • Table 7. Lung Cancer Diagnostics Others , by Region USD Million (2018-2023)
  • Table 8. Lung Cancer Diagnostics: by Application(USD Million)
  • Table 9. Lung Cancer Diagnostics Hospital Associated Labs , by Region USD Million (2018-2023)
  • Table 10. Lung Cancer Diagnostics Independent Diagnostic Laboratories , by Region USD Million (2018-2023)
  • Table 11. Lung Cancer Diagnostics Cancer Research Institutes , by Region USD Million (2018-2023)
  • Table 12. Lung Cancer Diagnostics Others , by Region USD Million (2018-2023)
  • Table 13. Lung Cancer Diagnostics: by Indication(USD Million)
  • Table 14. Lung Cancer Diagnostics Non-Small-Cell Lung Cancer [Large Cell Carcinoma, Adenocarcinoma, Squamous Cell Carcinoma, Others] , by Region USD Million (2018-2023)
  • Table 15. Lung Cancer Diagnostics Small-Cell Lung Cancer [Small-Cell Lung Carcinoma, Combined Small-Cell Lung Carcinoma] , by Region USD Million (2018-2023)
  • Table 16. Lung Cancer Diagnostics: by Imaging Techniques(USD Million)
  • Table 17. Lung Cancer Diagnostics MRI , by Region USD Million (2018-2023)
  • Table 18. Lung Cancer Diagnostics CT-Scan , by Region USD Million (2018-2023)
  • Table 19. Lung Cancer Diagnostics X-Ray , by Region USD Million (2018-2023)
  • Table 20. South America Lung Cancer Diagnostics, by Country USD Million (2018-2023)
  • Table 21. South America Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 22. South America Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 23. South America Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 24. South America Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 25. Brazil Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 26. Brazil Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 27. Brazil Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 28. Brazil Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 29. Argentina Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 30. Argentina Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 31. Argentina Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 32. Argentina Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 33. Rest of South America Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 34. Rest of South America Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 35. Rest of South America Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 36. Rest of South America Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 37. Asia Pacific Lung Cancer Diagnostics, by Country USD Million (2018-2023)
  • Table 38. Asia Pacific Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 39. Asia Pacific Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 40. Asia Pacific Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 41. Asia Pacific Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 42. China Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 43. China Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 44. China Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 45. China Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 46. Japan Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 47. Japan Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 48. Japan Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 49. Japan Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 50. India Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 51. India Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 52. India Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 53. India Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 54. South Korea Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 55. South Korea Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 56. South Korea Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 57. South Korea Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 58. Taiwan Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 59. Taiwan Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 60. Taiwan Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 61. Taiwan Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 62. Australia Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 63. Australia Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 64. Australia Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 65. Australia Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 70. Europe Lung Cancer Diagnostics, by Country USD Million (2018-2023)
  • Table 71. Europe Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 72. Europe Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 73. Europe Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 74. Europe Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 75. Germany Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 76. Germany Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 77. Germany Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 78. Germany Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 79. France Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 80. France Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 81. France Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 82. France Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 83. Italy Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 84. Italy Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 85. Italy Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 86. Italy Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 87. United Kingdom Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 88. United Kingdom Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 89. United Kingdom Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 90. United Kingdom Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 91. Netherlands Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 92. Netherlands Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 93. Netherlands Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 94. Netherlands Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 95. Rest of Europe Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 96. Rest of Europe Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 97. Rest of Europe Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 98. Rest of Europe Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 99. MEA Lung Cancer Diagnostics, by Country USD Million (2018-2023)
  • Table 100. MEA Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 101. MEA Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 102. MEA Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 103. MEA Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 104. Middle East Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 105. Middle East Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 106. Middle East Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 107. Middle East Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 108. Africa Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 109. Africa Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 110. Africa Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 111. Africa Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 112. North America Lung Cancer Diagnostics, by Country USD Million (2018-2023)
  • Table 113. North America Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 114. North America Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 115. North America Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 116. North America Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 117. United States Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 118. United States Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 119. United States Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 120. United States Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 121. Canada Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 122. Canada Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 123. Canada Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 124. Canada Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 125. Mexico Lung Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 126. Mexico Lung Cancer Diagnostics, by Application USD Million (2018-2023)
  • Table 127. Mexico Lung Cancer Diagnostics, by Indication USD Million (2018-2023)
  • Table 128. Mexico Lung Cancer Diagnostics, by Imaging Techniques USD Million (2018-2023)
  • Table 129. Lung Cancer Diagnostics: by Type(USD/Units)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Company Basic Information, Sales Area and Its Competitors
  • Table 147. Company Basic Information, Sales Area and Its Competitors
  • Table 148. Company Basic Information, Sales Area and Its Competitors
  • Table 149. Company Basic Information, Sales Area and Its Competitors
  • Table 150. Lung Cancer Diagnostics: by Type(USD Million)
  • Table 151. Lung Cancer Diagnostics CA Test , by Region USD Million (2025-2030)
  • Table 152. Lung Cancer Diagnostics HER2 Tests , by Region USD Million (2025-2030)
  • Table 153. Lung Cancer Diagnostics ALK Tests , by Region USD Million (2025-2030)
  • Table 154. Lung Cancer Diagnostics Angiogenesis Inhibitor , by Region USD Million (2025-2030)
  • Table 155. Lung Cancer Diagnostics KRAS Mutation Tests , by Region USD Million (2025-2030)
  • Table 156. Lung Cancer Diagnostics Others , by Region USD Million (2025-2030)
  • Table 157. Lung Cancer Diagnostics: by Application(USD Million)
  • Table 158. Lung Cancer Diagnostics Hospital Associated Labs , by Region USD Million (2025-2030)
  • Table 159. Lung Cancer Diagnostics Independent Diagnostic Laboratories , by Region USD Million (2025-2030)
  • Table 160. Lung Cancer Diagnostics Cancer Research Institutes , by Region USD Million (2025-2030)
  • Table 161. Lung Cancer Diagnostics Others , by Region USD Million (2025-2030)
  • Table 162. Lung Cancer Diagnostics: by Indication(USD Million)
  • Table 163. Lung Cancer Diagnostics Non-Small-Cell Lung Cancer [Large Cell Carcinoma, Adenocarcinoma, Squamous Cell Carcinoma, Others] , by Region USD Million (2025-2030)
  • Table 164. Lung Cancer Diagnostics Small-Cell Lung Cancer [Small-Cell Lung Carcinoma, Combined Small-Cell Lung Carcinoma] , by Region USD Million (2025-2030)
  • Table 165. Lung Cancer Diagnostics: by Imaging Techniques(USD Million)
  • Table 166. Lung Cancer Diagnostics MRI , by Region USD Million (2025-2030)
  • Table 167. Lung Cancer Diagnostics CT-Scan , by Region USD Million (2025-2030)
  • Table 168. Lung Cancer Diagnostics X-Ray , by Region USD Million (2025-2030)
  • Table 169. South America Lung Cancer Diagnostics, by Country USD Million (2025-2030)
  • Table 170. South America Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 171. South America Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 172. South America Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 173. South America Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 174. Brazil Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 175. Brazil Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 176. Brazil Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 177. Brazil Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 178. Argentina Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 179. Argentina Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 180. Argentina Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 181. Argentina Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 182. Rest of South America Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 183. Rest of South America Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 184. Rest of South America Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 185. Rest of South America Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 186. Asia Pacific Lung Cancer Diagnostics, by Country USD Million (2025-2030)
  • Table 187. Asia Pacific Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 188. Asia Pacific Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 189. Asia Pacific Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 190. Asia Pacific Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 191. China Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 192. China Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 193. China Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 194. China Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 195. Japan Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 196. Japan Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 197. Japan Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 198. Japan Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 199. India Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 200. India Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 201. India Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 202. India Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 203. South Korea Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 204. South Korea Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 205. South Korea Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 206. South Korea Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 207. Taiwan Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 208. Taiwan Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 209. Taiwan Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 210. Taiwan Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 211. Australia Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 212. Australia Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 213. Australia Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 214. Australia Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 215. Rest of Asia-Pacific Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 216. Rest of Asia-Pacific Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 217. Rest of Asia-Pacific Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 218. Rest of Asia-Pacific Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 219. Europe Lung Cancer Diagnostics, by Country USD Million (2025-2030)
  • Table 220. Europe Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 221. Europe Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 222. Europe Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 223. Europe Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 224. Germany Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 225. Germany Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 226. Germany Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 227. Germany Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 228. France Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 229. France Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 230. France Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 231. France Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 232. Italy Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 233. Italy Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 234. Italy Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 235. Italy Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 236. United Kingdom Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 237. United Kingdom Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 238. United Kingdom Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 239. United Kingdom Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 240. Netherlands Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 241. Netherlands Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 242. Netherlands Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 243. Netherlands Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 244. Rest of Europe Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 245. Rest of Europe Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 246. Rest of Europe Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 247. Rest of Europe Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 248. MEA Lung Cancer Diagnostics, by Country USD Million (2025-2030)
  • Table 249. MEA Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 250. MEA Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 251. MEA Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 252. MEA Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 253. Middle East Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 254. Middle East Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 255. Middle East Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 256. Middle East Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 257. Africa Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 258. Africa Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 259. Africa Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 260. Africa Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 261. North America Lung Cancer Diagnostics, by Country USD Million (2025-2030)
  • Table 262. North America Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 263. North America Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 264. North America Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 265. North America Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 266. United States Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 267. United States Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 268. United States Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 269. United States Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 270. Canada Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 271. Canada Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 272. Canada Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 273. Canada Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 274. Mexico Lung Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 275. Mexico Lung Cancer Diagnostics, by Application USD Million (2025-2030)
  • Table 276. Mexico Lung Cancer Diagnostics, by Indication USD Million (2025-2030)
  • Table 277. Mexico Lung Cancer Diagnostics, by Imaging Techniques USD Million (2025-2030)
  • Table 278. Lung Cancer Diagnostics: by Type(USD/Units)
  • Table 279. Research Programs/Design for This Report
  • Table 280. Key Data Information from Secondary Sources
  • Table 281. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Lung Cancer Diagnostics: by Type USD Million (2018-2023)
  • Figure 5. Global Lung Cancer Diagnostics: by Application USD Million (2018-2023)
  • Figure 6. Global Lung Cancer Diagnostics: by Indication USD Million (2018-2023)
  • Figure 7. Global Lung Cancer Diagnostics: by Imaging Techniques USD Million (2018-2023)
  • Figure 8. South America Lung Cancer Diagnostics Share (%), by Country
  • Figure 9. Asia Pacific Lung Cancer Diagnostics Share (%), by Country
  • Figure 10. Europe Lung Cancer Diagnostics Share (%), by Country
  • Figure 11. MEA Lung Cancer Diagnostics Share (%), by Country
  • Figure 12. North America Lung Cancer Diagnostics Share (%), by Country
  • Figure 13. Global Lung Cancer Diagnostics: by Type USD/Units (2018-2023)
  • Figure 14. Global Lung Cancer Diagnostics share by Players 2023 (%)
  • Figure 15. Global Lung Cancer Diagnostics share by Players (Top 3) 2023(%)
  • Figure 16. Global Lung Cancer Diagnostics share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Roche Diagnostics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Roche Diagnostics (Switzerland) Revenue: by Geography 2023
  • Figure 20. BioMérieux (France) Revenue, Net Income and Gross profit
  • Figure 21. BioMérieux (France) Revenue: by Geography 2023
  • Figure 22. Qiagen (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Qiagen (Germany) Revenue: by Geography 2023
  • Figure 24. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 25. Agilent Technologies (United States) Revenue: by Geography 2023
  • Figure 26. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 28. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 29. Sanofi (France) Revenue: by Geography 2023
  • Figure 30. Janssen Pharmaceuticals (Belgium) Revenue, Net Income and Gross profit
  • Figure 31. Janssen Pharmaceuticals (Belgium) Revenue: by Geography 2023
  • Figure 32. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 33. GE Healthcare (United States) Revenue: by Geography 2023
  • Figure 34. Hologic (United States) Revenue, Net Income and Gross profit
  • Figure 35. Hologic (United States) Revenue: by Geography 2023
  • Figure 36. Koninklijke Philips N.V (Netherlands) Revenue, Net Income and Gross profit
  • Figure 37. Koninklijke Philips N.V (Netherlands) Revenue: by Geography 2023
  • Figure 38. Danaher (United States) Revenue, Net Income and Gross profit
  • Figure 39. Danaher (United States) Revenue: by Geography 2023
  • Figure 40. Illumina, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 41. Illumina, Inc. (United States) Revenue: by Geography 2023
  • Figure 42. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 43. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 44. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 45. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2023
  • Figure 46. Quest Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 47. Quest Diagnostics (United States) Revenue: by Geography 2023
  • Figure 48. Courtagen Life Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 49. Courtagen Life Sciences, Inc. (United States) Revenue: by Geography 2023
  • Figure 50. DiagnoCure Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 51. DiagnoCure Inc. (Canada) Revenue: by Geography 2023
  • Figure 52. BioMark Diagnostics Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 53. BioMark Diagnostics Inc. (Canada) Revenue: by Geography 2023
  • Figure 54. HalioDx SAS (France) Revenue, Net Income and Gross profit
  • Figure 55. HalioDx SAS (France) Revenue: by Geography 2023
  • Figure 56. NeoGenomics (United States) Revenue, Net Income and Gross profit
  • Figure 57. NeoGenomics (United States) Revenue: by Geography 2023
  • Figure 58. Global Lung Cancer Diagnostics: by Type USD Million (2025-2030)
  • Figure 59. Global Lung Cancer Diagnostics: by Application USD Million (2025-2030)
  • Figure 60. Global Lung Cancer Diagnostics: by Indication USD Million (2025-2030)
  • Figure 61. Global Lung Cancer Diagnostics: by Imaging Techniques USD Million (2025-2030)
  • Figure 62. South America Lung Cancer Diagnostics Share (%), by Country
  • Figure 63. Asia Pacific Lung Cancer Diagnostics Share (%), by Country
  • Figure 64. Europe Lung Cancer Diagnostics Share (%), by Country
  • Figure 65. MEA Lung Cancer Diagnostics Share (%), by Country
  • Figure 66. North America Lung Cancer Diagnostics Share (%), by Country
  • Figure 67. Global Lung Cancer Diagnostics: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Roche Diagnostics (Switzerland)
  • BioMérieux (France)
  • Qiagen (Germany)
  • Agilent Technologies (United States)
  • AstraZeneca (United Kingdom)
  • Sanofi (France)
  • Janssen Pharmaceuticals (Belgium)
  • GE Healthcare (United States)
  • Hologic (United States)
  • Koninklijke Philips N.V (Netherlands)
  • Danaher (United States)
  • Illumina, Inc. (United States)
  • Abbott Laboratories (United States)
  • Thermo Fisher Scientific, Inc. (United States)
  • Quest Diagnostics (United States)
  • Courtagen Life Sciences, Inc. (United States)
  • DiagnoCure Inc. (Canada)
  • BioMark Diagnostics Inc. (Canada)
  • HalioDx SAS (France)
  • NeoGenomics (United States)
Additional players considered in the study are as follows:
NanoString Technologies, Inc. (United States) , Myriad Genetics, Inc. (United States) , BioTheranostics, Inc. (United States) , EXACT Sciences Corporation (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 218 Pages 76 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Lung Cancer Diagnostics Market Quantitative research analysis
Global Lung Cancer Diagnostics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Roche Diagnostics (Switzerland), BioMérieux (France), Qiagen (Germany), Agilent Technologies (United States), AstraZeneca (United Kingdom), Sanofi (France), Janssen Pharmaceuticals (Belgium), GE Healthcare (United States), Hologic (United States), Koninklijke Philips N.V (Netherlands), Danaher (United States), Illumina, Inc. (United States), Abbott Laboratories (United States), Thermo Fisher Scientific, Inc. (United States), Quest Diagnostics (United States), Courtagen Life Sciences, Inc. (United States), DiagnoCure Inc. (Canada), BioMark Diagnostics Inc. (Canada), HalioDx SAS (France) and NeoGenomics (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"A Rising Trend in Campaigning For Increasing Awareness of the Symptoms of Lung Cancer " is seen as one of major influencing trends for Lung Cancer Diagnostics Market during projected period 2023-2030.
The Lung Cancer Diagnostics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Lung Cancer Diagnostics Market Report?

Have a Query? Click Here

Other Related Reports

Diagnostic Biomarkers Comprehensive Study by Type (Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers), Application (Hospitals, Cancer Research Institutes, Diagnostic Labs), Biomarkers val...
$ 3650
Hormonal Implants Comprehensive Study by Type (Levonorgestrel Hormonal Implants, Etonogestrel Hormonal Implants), Application (Hospitals, Clinics, Others) Players and Region - Global Market Outlook t...
$ 3500
Weight Loss Services Comprehensive Study by Type (Weight Loss Diet (Food, Beverages), Fitness Equipment (Cardiovascular, Strength Training, Infrared Light Therapy, & Others), Surgical Equipment (Bari...
$ 3750
ATP Assay Comprehensive Study by Type (Consumables & Accessories {Reagents & Kits, Microplates, Other Consumables & Accessories}, Instruments {Luminometers, Spectrophotometers}), Application (Contami...
$ 3750
Digestive System Anatomical Model Comprehensive Study by Type (Adult Digestive System Anatomical Model, Children Digestive System Anatomical Model), Application (Hospital & Clinic, Academic Institute...
$ 3650
Dental Fiber Post Comprehensive Study by Type (Tapered, Parallel, Combination), Application (Hospitals, Dental Clinics, Other), Distribution Channel (Online, Offline) Players and Region - Global Mark...
$ 3500